CONTINUED SUPERIORITY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND BEYOND 1 YEAR

被引：0

作者：

Hochhaus, A. ^{[1
]}

Lobo, C. ^{[2
]}

Pasquini, R. ^{[3
]}

Clark, R. ^{[4
]}

Kim, D. W. ^{[5
]}

Issaragrisil, S. ^{[6
]}

le Coutre, P. ^{[7
]}

Reiffers, J. ^{[8
]}

Kantarjian, H. ^{[9
]}

Saglio, G. ^{[10
]}

Edrich, P. ^{[11
]}

Hoenekopp, A. ^{[11
]}

Gallagher, N. ^{[11
]}

Larson, R. ^{[12
]}

Hughes, T. ^{[13
]}

机构：

[1] Univ Klinikum Jena, Jena, Germany

[2] HEMORIO, Rio De Janeiro, Brazil

[3] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil

[4] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England

[5] Catholic Univ Korea, Seoul, South Korea

[6] Siriraj Hosp, Fac Med, Bangkok, Thailand

[7] Univ Med Berlin, Berlin, Germany

[8] CRLCC, Inst Bergonie, Bordeaux, France

[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[10] Univ Turin, Orbassano, Italy

[11] Novartis Pharma AG, Basel, Switzerland

[12] Univ Chicago, Chicago, IL USA

[13] Royal Adelaide Hosp, Adelaide, SA 5000, Australia

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1113

引用

页码：459 / 459

页数：1